MAD0004J08 / Toscana Life Sci - LARVOL DELTA

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection. (PubMed, Nat Commun) - P1 | "A single dose administration of MAD0004J08 is also sufficient to effectively neutralize major SARS-CoV-2 variants of concern (alpha, beta, gamma and delta). MAD0004J08 can be a major advancement in the prophylaxis and clinical management of COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

MAD0004J08: Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease. (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Toscana Life Sciences Sviluppo s.r.l. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19. (clinicaltrials.gov) - P2/3 | N=800 | Active, not recruiting | Sponsor: Toscana Life Sciences Sviluppo s.r.l. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19. (clinicaltrials.gov) - P2/3; N=800; Recruiting; Sponsor: Toscana Life Sciences Sviluppo s.r.l.

Clinical • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

MAD0004J08: Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease. (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: Toscana Life Sciences Sviluppo s.r.l.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases